Summary of COVID-19 vaccine candidates and related agreements
This table tracks various development, production, supply, funding, and intellectual property agreements for COVID-19 vaccine candidates. The information included in the table was sourced from publicly available information such as company websites and reputable news sources. In addition, the WHO Draft Landscape of COVID-19 Candidate Vaccines was used as a central reference point to identify new vaccine candidates. Please note: the contents of this table are formed from GHIAA’s understanding and interpretation of publicly available information. The purpose of this table is to begin to identify agreements related to the COVID-19 response, however it should not be relied upon to provide a complete overview of the current landscape.
Vaccine Developer(s) Current development stage Funders Related agreements/partnerships/collaborations candidate/technology AZD1222 (previously Jenner Institute, University Phase 3 clinical trial UK Government Supply agreement between AstraZeneca & Inclusive ChAdOx1) of Oxford (academic (government) Vaccines Alliance Non-Replicating Viral Vector institution) ISRCTN Registry Identifier: University of Oxford ISRCTN89951424 (Phase 3) Licensing, manufacturing, and distribution agreement AstraZeneca (multinational (academic institution) between R-Pharm and AstraZeneca pharmaceutical company) ClinicalTrials.gov Identifiers BARDA (government) Serum Institute of India (U.S.): Supply agreement between Symbiosis CEPI (funder) (vaccine manufacturer) NCT04456595 (Phase 3) Pharmaceutical and AstraZeneca NCT04352608 (Phase 1/2) Gavi, the Vaccine IQVIA (contract research NCT04383574 (Phase 1/2) Alliance (multilateral Supply agreement for 300 million doses between U.S. organization) organization) Government and AstraZeneca EU Clinical Trials Register Identifier: 2020-001228-32 Supply agreement for100 million doses (30 million by (Phase 2b/3) Sept. 2020) between U.K. Government and 2020-001072-15 (Phase AstraZeneca 1/2) Supply/manufacturing agreement between Brazilian Pan African Clinical Trials Government and AstraZeneca Registry Identifier: PACTR202006922165132 Manufacturing agreement between AstraZeneca & (Phase 1/2) Catalent
Supply & licensing agreement between Serum Institute of India and AstraZeneca
Manufacturing agreement for clinical trials between Serum Institute of India and AstraZeneca
Researched by: Nathan Gardner 1 Last update date: August 1, 2020
Vaccine Developer(s) Current development stage Funders Related agreements/partnerships/collaborations candidate/technology
Manufacturing, procurement and distribution agreement for 300 million doses between CEPI, Gavi, and AstraZeneca
Manufacturing agreement (1-year) between Oxford Biomedica & AstraZeneca
Funding partnership between BARDA and AstraZeneca
Funding partnership between CEPI, Gavi, and AstraZeneca
Development agreement between Oxford & AstraZeneca
Development collaboration between IQVIA & AstraZeneca mRNA-1273 Moderna (biotechnology Phase 3 clinical trial NIAID (government) 10-year strategic collaboration agreement between LNP-encapsulated mRNA company) Moderna & Lonza BARDA (government) ClinicalTrials.gov Identifiers Lonza (multinational (U.S.): CEPI (funder) Funding partnership between Moderna & CEPI pharmaceutical company) NCT04283461 (Phase 1) Operation Warp Speed NIAID (government) NCT04405076 (Phase 2) Funding partnership between Moderna & BARDA (government) NCT04470427 (Phase 3) Manufacturing agreement between Moderna & Laboratorios Farmacéuticos Rovi
Inactivated vaccine Wuhan Institute of Phase 3 clinical trial Biological Products (state- owned biotechnology Chinese Clinical Trials company) Registry Identifiers: ChiCTR2000031809 (Phase Sinopharm (state-owned 1/2) biotechnology company)
Researched by: Nathan Gardner 2 Last update date: August 1, 2020
Vaccine Developer(s) Current development stage Funders Related agreements/partnerships/collaborations candidate/technology ChiCTR2000034780 (Phase 3) Inactivated vaccine Beijing Institute of Biological Phase 3 clinical trial Products (state-owned biotechnology company) Chinese Clinical Trials Registry Identifier: Sinopharm (state-owned ChiCTR2000032459 (Phase biotechnology company) 1/2) ChiCTR2000034780 (Phase 3) CoronaVac Sinovac (state-owned Phase 3 clinical trial Advantech Capital Development agreement between Sinovac & Instituto Inactivated + alum biotechnology company) (general industry) Butatan ClinicalTrials.gov Identifiers Instituto Butatan (research Vivo Capital (general (U.S.): Clinical trial and manufacturing agreement between institute) industry) NCT04456595 (Phase 3) Sinovac & PT BioFarma NCT04352608 (Phase 1/2) Government of China NCT04383574 (Phase 1/2) (government)
Bacillus Calmette-Guerin University of Melbourne Phase 2/3 clinical trial Gates Foundation Funding agreement between Gates and University of (BCG) live-attenuated vaccine (academic institution) (funder) Melbourne ClinicalTrials.gov Identifiers Murdoch Children’s Sarah and Lachlan (U.S.): Research Institute (research Murdoch (funder) NCT04327206, institute) NCT04328441 The Royal Children’s Radboud University Medical Hospital Foundation Center (non-profit) (non-profit) Faustman Lab at The Minderoo Massachusetts General Foundation (non-profit) Hospital (research institute) South Australian government (funder) NAB Foundation (non- profit)
Researched by: Nathan Gardner 3 Last update date: August 1, 2020
Vaccine Developer(s) Current development stage Funders Related agreements/partnerships/collaborations candidate/technology Calvert-Jones Foundation (non-profit / funder) HUG Foundation (non- profit / funder) River Capital (general industry) Individual donors
BNT162b2 Pfizer (multinational Phase 2/3 clinical trial Material transfer and Collaboration agreement LNP-mRNA pharmaceutical company) between Pfizer & BioNTech EU Clinical Trials Register BioNTech (biotechnology Identifier: 2020-001038-36 Licensing & equity investment agreement between company) (Phase 1/2) Fosun and BioNTech Fosun Pharma (multinational ClinicalTrials.gov Identifier Supply agreement for 100 million doses between U.S. pharmaceutical company) (U.S.): NCT04368728 (Phase Government, Pfizer & BioNTech 1/2) Supply agreement for 120 million doses between Chinese Clinical Trial Government of Japan, Pfizer, & BioNTech Registry Identifier: ChiCTR2000034825 (Phase Clinical trial agreement between Pfizer, BioNTech, 1/2) The University of Rochester Medical Center and Rochester Regional Health
Adjuvanted recombinant Anhui Zhifei Longcom Phase 2 clinical trial Development partnership between Anhui Zhifei protein (RBD-Dimer) Biopharmaceutical Longcom Biopharmaceutical & Institute of Protein Subunit (biotechnology company) ClinicalTrials.gov Identifier Microbiology, Chinese Academy of Sciences (U.S.): Institute of Microbiology, NCT04445194 (Phase 1) Chinese Academy of NCT04466085 (Phase 2) Sciences (academic
institution)
Researched by: Nathan Gardner 4 Last update date: August 1, 2020
Vaccine Developer(s) Current development stage Funders Related agreements/partnerships/collaborations candidate/technology Ad5-nCoV CanSino Biologics Phase 2 clinical trial Development agreement between National Research Adenovirus Type 5 Vector, (biotechnology company / Council Canada & CanSino Biologics Non-Replicating Viral Vector vaccine manufacturer) Chinese Clinical Trial Registry Identifiers: Development agreement between Sartorius, Beijing Beijing Institute of ChiCTR2000030906 (Phase Institute of Biotechnology & CanSino Biologics Biotechnology (academic 1), ChiCTR2000031781 institution) (Phase 2) 2014 Licensing agreement (between CanSino and National Research Council Canada – for cell line) ClinicalTrials.gov Identifier (U.S.): NCT04313127 NVX-CoV2373 Novavax (biotechnology Phase 1/2 clinical trial Operation Warp Speed Manufacturing agreement between AGC Biologics & Full length recombinant SARs company) (government) Novavax CoV-2 glycoprotein ClinicalTrials.gov Identifier CEPI (funder) nanoparticle vaccine (U.S.): Funding agreement between Novavax and the U.S. adjuvanted with Matrix M – NCT04368988 (Phase 1/2) U.S. Department of Department of Defense Protein Subunit Defense (government) Funding agreement between Novavax and CEPI
Funding agreement including the delivery of 100 million doses starting late 2020 between Operation Warp Speed and Novavax
Contract development and manufacturing agreement between Emergent & Novavax
Phase 1 clinical trial agreement between Nucleus & Novavax
ZyCoV-D: DNA plasmid Cadila Healthcare Limited Phase 1/2 clinical trial vaccine (multinational pharmaceutical company) Chinese Clinical Trial Registry Identifier:
Researched by: Nathan Gardner 5 Last update date: August 1, 2020
Vaccine Developer(s) Current development stage Funders Related agreements/partnerships/collaborations candidate/technology CTRI/2020/07/026352 (Phase 1/2) DNA plasmid vaccine Osaka University (academic Phase 1/2 clinical trial Collaboration between Osaka University, AnGes & institution) Takara Bio Japanese Clinical Trial AnGes (biotechnology Identifier: Manufacturing agreement between Cytiva & Takara company) JapicCTI-205328 (Phase I) Bio Takara Bio (biotechnology company) ClinicalTrials.gov Identifier (U.S.): NCT04463472 (Phase 1/2) Inactivated vaccine Institute of Medical Biology, Phase 1/2 clinical trial Jack Ma Foundation Chinese Academy of (funder) Medical Sciences (academic ClinicalTrials.gov Identifiers institution) (U.S.): NCT04412538 (Phase I) NCT04470609 (Phase 1/2)
RBD-based vaccine Kentucky Bioprocessing, Inc Phase 1/2 clinical trial Protein Subunit (British American Tobacco) (general industry) ClinicalTrials.gov Identifiers (U.S.): NCT04473690 (Phase 1/2) Ad26 Non-Replicating Viral Janssen Pharmaceutical Phase 1/2 clinical trial BARDA (government) Development partnership between Beth Israel Vector Companies (multinational Deaconess Medical Center & Janssen pharmaceutical company) 5-Year CDMO services agreement between Emergent & Janssen
Manufacturing agreement between Catalent & Janssen
LUNAR-COV19, mRNA Arcturus (biotechnology Phase 1/2 clinical trial Collaboration between Arcturus & Duke-NUS medical company) school
Researched by: Nathan Gardner 6 Last update date: August 1, 2020
Vaccine Developer(s) Current development stage Funders Related agreements/partnerships/collaborations candidate/technology Duke-NUS (academic ClinicalTrials.gov Identifiers Manufacturing agreement between Arcturus & institution) (U.S.): Catalent NCT04480957 (Phase 1/2)
INO-4800 Inovio Pharmaceuticals Phase 1 clinical trial Gates Foundation Manufacturing partnership between Richter-Helm DNA plasmid vaccine with (biotechnology company) (funder) BioLogics GmbH & Co. KG, VGXI & Inovio electroporation ClinicalTrials.gov Identifiers International Vaccine CEPI (funder) (U.S.): Technology transfer and manufacturing agreement Institute (multilateral NCT04447781 (Phase 1/2) U.S. Department of between Ology Bioservices & Inovio, funded by U.S. organization) NCT04336410 (Phase 1/2) Defense (government) Department of Defense
Funding agreement between CEPI & Inovio
Funding agreement between Gates & Inovio
Phase 1/2 clinical trial partnership between IVI, Seoul National University Hospital & Inovio bacTRL-Spike Symvivo (biotechnology Phase 1 clinical trial Development partnership for Phase 1 Trial between company) Symvivo, Vaccine Evaluation Center, BC Children’s ClinicalTrials.gov Identifier Hospital Research Institute, University of British Vaccine Evaluation Center (U.S.): Columbia, the Canadian Center for Vaccinology, (academic institution) NCT04334980 Dalhousie University & IWK Health Centre in Halifax BC Children’s Hospital Research Institute (academic institution) University of British Columbia (academic institution) Canadian Center for Vaccinology (research institute) Dalhousie University (academic institution)
Researched by: Nathan Gardner 7 Last update date: August 1, 2020
Vaccine Developer(s) Current development stage Funders Related agreements/partnerships/collaborations candidate/technology IWK Health Centre in Halifax (academic institution)
LV-SMENP-DC Shenzhen Geno-Immune Phase 1 clinical trial Dendritic cells modified with Medical Institute lentiviral vector expressing (government) ClinicalTrials.gov Identifier synthetic minigene based on (U.S.): domains of selected viral NCT04276896 proteins administered with antigen-specific cytotoxic T lymphocytes Artificial antigen-presenting Shenzhen Geno-Immune Phase 1 clinical trial cells modified with lentiviral Medical Institute vector expressing synthetic (government) ClinicalTrials.gov Identifier minigene based on domains (U.S.): of selected viral proteins NCT04299724 The RNA Printer™ CureVac (biotechnology Phase 1 clinical trial European Investment Funding agreement between CEPI & CureVac mRNA-based COVID-19 company) Bank (multilateral vaccine ClinicalTrials.gov Identifier organization) Funding agreement between German government & The Institute for Tropical (U.S.): CureVac Medicine in Tübingen European Commission NCT04449276 (academic institution) (multilateral organization) CEPI (funder) Gates Foundation (funder) DARPA (government) German Government (government)
Researched by: Nathan Gardner 8 Last update date: August 1, 2020
Vaccine Developer(s) Current development stage Funders Related agreements/partnerships/collaborations candidate/technology GX-19 Consortium: Genexine, Phase 1 clinical trial Finnish Government MOU for human trials in Indonesia between DNA Vaccine Binex, GenNBio, (government) Genexine & Kalbe) International Vaccine ClinicalTrials.gov Identifier Institute, Korea Advanced (U.S.): MOU between Binex & Genexine Institute of Science and NCT04445389 (Phase 1/2a) Technology and Pohang Joint venture for Indonesian clinical trial between University of Science and Kingen Holdings & Genexine Technology (product development partnership)
Adeno-based, Non- Gamaleya Research Institute Phase 1 clinical trial Replicating Viral Vector (research institute) ClinicalTrials.gov Identifiers Sechenov University (U.S.): (academic institution) NCT04436471 (Phase 1) NCT04437875 (Phase 1) SCB-2019 Clover Biopharmaceuticals Phase 1 clinical trial CEPI (funder) Development agreement between GSK & Clover Native like Trimeric subunit Inc (multinational Spike Protein vaccine, Protein pharmaceutical company) ClinicalTrials.gov Identifier Development agreement between Dynavax & Clover Subunit (U.S.): GSK (multinational NCT04405908 (Phase 1) Funding partnership between CEPI & Clover pharmaceutical company) Dynavax (biotechnology company)
LNP-nCoVsaRNA Imperial College London Phase 1 clinical trial U.K. Government Partnership between Morningside Ventures & (academic institution) (funder) Imperial College to create VacEquity ISRCTN Registry Identifier: ISRCTN17072692
Researched by: Nathan Gardner 9 Last update date: August 1, 2020
Vaccine Developer(s) Current development stage Funders Related agreements/partnerships/collaborations candidate/technology ARCoV People's Liberation Army Phase 1 clinical trial Development partnership between People's mRNA Academy of Military Liberation Army Academy of Military Sciences & Sciences (government) Chinese Clinical Trial Walvax Registry Identifier: Walvax Biotech ChiCTR2000034112 (biotechnology company)
Recombinant spike protein Vaxine Pty Ltd Phase 1 clinical trial Collaboration for Phase 1 Trial with Advax™ adjuvant, (biotechnology company) Between Flinders University & Vaxine Protein Subunit ClinicalTrials.gov Identifier Medytox (multinational (U.S.): Technical collaboration partnership between Oracle, pharmaceutical company) NCT04453852 Flinders University & Vaxine
Manufacturing agreement between Sypharma & Vaxine Plant-derived VLP adjuvanted Medicago (biotechnology Phase 1 Canadian Institutes for Collaboration between Medicago & Laval University with GSK or Dynavax adjs. company) Health Research ClinicalTrials.gov Identifier (government / funder) Development agreement between Medicago & GSK Université Laval (academic (U.S.): institution) NCT04450004 (Phase I) GSK (multinational pharmaceutical company)
Whole-Virion Inactivated Bharat Biotech Phase 1 Vaccine (biotechnology company) Chinese Clinical Trial Registry Identifier: CTRI/2020/07/026300
Researched by: Nathan Gardner 10 Last update date: August 1, 2020
Vaccine Developer(s) Current development stage Funders Related agreements/partnerships/collaborations candidate/technology Molecular clamp stabilized University of Queensland Phase 1 Queensland Development & manufacturing agreement between Spike protein with MF59 (academic institution) Government the University of Queensland, CEPI & CSL adjuvant Australian New Zealand (government) CSL (biotechnology Protein Subunit Clinical Trial Registry company) Australian Government Identifier: (government) Seqirus (biotechnology ACTRN12620000674932p company / vaccine Paul Ramsey Foundation manufacturer) (funder) CEPI (funder) CSL (biotechnology company)
S-2P protein + CpG 1018 Medigen Vaccine Biologics Phase 1 Protein Subunit Corporation (biotechnology company / vaccine NCT04487210 (Phase 1) manufacturer) NIAID (government) Dynavax (biotechnology company)
Inactivated whole virus National Research Centre, Pre-clinical Egypt (research institute)
S,S1,S2,RBD &N National Research Centre, Pre-clinical DNA plasmid vaccine Egypt (research institute)
PittCoVacc University of Pittsburgh Pre-clinical CEPI (funder) Funding partnership between CEPI & University of Microneedle arrays S1 Center for Vaccine Research Pittsburgh subunit, Protein Subunit (academic institution)
Ii-Key peptide Generex Biotechnology Pre-clinical Development & commercial licensing between (biotechnology company) partners in China & Generex
EpiVax (biotechnology Development agreement between EpiVax & Generex company)
Researched by: Nathan Gardner 11 Last update date: August 1, 2020
Vaccine Developer(s) Current development stage Funders Related agreements/partnerships/collaborations candidate/technology Oral recombinant vaccine Vaxart (biotechnology Pre-clinical Operation Warp Speed Development & manufacturing agreement for phase gene-based vaccine company) (government) 1 study between Emergent & Vaxart
Manufacturing agreement between KindredBio & Vaxart) DNA-based vaccine Takis Biotech Pre-clinical Development agreement between Applied DNA & (biotechnology company) Takis Applied DNA Sciences (biotechnology company) Evvivax (biotechnology company)
MVA-S IDIBAPS-Hospital Clinic, Pre-clinical Non-replicating viral vector Spain (non-profit)
AdCOVID Altimmune (biotechnology Pre-clinical Collaboration between UAB & Altimmune Intranasal vaccine, company) adenovirus-based NasoVAX Teaming agreement between Altimmune & DynPort DynPort (biotechnology expressing SARS2-CoV spike company) protein, Non-Replicating Viral Vector T-COVIDTM Altimmune (biotechnology Pre-clinical company)
DNA with electroporation OPENCORONA Project – Pre-clinical Horizon 2020 (European Karolinska Institute & Cobra Union) (funder) Biologics (product development partnership)
DNA with electroporation Chula Vaccine Research Pre-clinical Center (academic institution)
Plasmid DNA Immunomic Therapeutics, Pre-clinical Development agreement between Immunomic, Needle-Free Delivery Inc. (biotechnology EpiVax & PharmaJet company) Researched by: Nathan Gardner 12 Last update date: August 1, 2020
Vaccine Developer(s) Current development stage Funders Related agreements/partnerships/collaborations candidate/technology EpiVax (biotechnology company) PharmaJet (general industry)
DNA vaccine BioNet Asia (biotechnology Pre-clinical Collaboration between the Thai National Control company / vaccine Laboratory & BioNet Asia manufacturer) msDNA vaccine University of Waterloo Pre-clinical Natural Sciences and (academic institution) Engineering Research Council of Canada Mediphage Bioceuticals (government) (biotechnology company)
DNA vaccine Entos Pharmaceuticals Pre-clinical Development agreement between EpiVax & Entos (biotechnology company) Manufacturing agreement between Cytiva & Entos
Inactivated vaccine Beijing Minhai Pre-clinical Biotechnology Co., Ltd. (biotechnology company / vaccine manufacturer)
Inactivated vaccine Osaka University (academic Pre-clinical institution) BIKEN (biotechnology company) NIBIOHN (government)
Inactivated + CpG 1018 Sinovac (biotechnology Pre-clinical Development agreement between Sinovac & Dynavax vaccine company / vaccine manufacturer)
Researched by: Nathan Gardner 13 Last update date: August 1, 2020
Vaccine Developer(s) Current development stage Funders Related agreements/partnerships/collaborations candidate/technology Dynavax (biotechnology company)
Inactivated + CpG 1018 Valneva (biotechnology Pre-clinical Development agreement between Valneva & vaccine company) Dynavax Dynavax (biotechnology company)
Inactivated vaccine Research Institute for Pre-clinical Biological Safety Problems, Republic of Kazakhstan (government)
Codon deoptimized live Codagenix (biotechnology Pre-clinical Adjuvant Capital Manufacturing & distribution agreement between attenuated vaccine company) (funder) Codagenix & Serum Institute of India Serum Institute of India (vaccine manufacturer)
Codon deoptimized live Indian Immunologicals Ltd Pre-clinical Collaboration between Indian Immunologicals & attenuated vaccine (biotechnology company / Griffith University vaccine manufacturer) Griffith University (academic institution)
AAVCOVID Massachusetts Eye and Ear Pre-clinical Manufacturing agreement between Massachusetts Adeno-associated virus (non-profit) Eye and Ear, Massachusetts General Hospital & vector, Non-Replicating Viral AveXis Massachusetts General Vector Hospital (non-profit) AveXis (biotechnology company) – Subsidiary of Novartis (multinational pharmaceutical company)
Researched by: Nathan Gardner 14 Last update date: August 1, 2020
Vaccine Developer(s) Current development stage Funders Related agreements/partnerships/collaborations candidate/technology MVA encoded VLP, Non- GeoVax (biotechnology Pre-clinical Development agreement between GeoVax & Replicating Viral Vector company) BravoVax BravoVax (biotechnology company / vaccine manufacturer)
Replication defective Simian ReiThera (biotechnology Pre-clinical Strategic collaboration agreement between ReiThera, Adenovirus (GRAd) encoding company) Leukocare & Univercells SARS-CoV-2 S LEUKOCARE (biotechnology Non-Replicating Viral Vector Manufacturing partnership between Exyte & company) Univercells Univercells (vaccine manufacturer)
MVA-S encoded, Non- DZIF – German Center for Pre-clinical CEPI (funder) Manufacturing partnership between DZIF & IDT for replicating viral vector Infection Research pre-clinical trials (government) IDT Biologika GmbH (vaccine manufacturer)
[E1-, E2b-, E3-] hAd5- ImmunityBio, Inc. Pre-clinical Joint development, manufacture, and marketing COVID19-Spike/Nucleocapsid (biotechnology company) agreement between ImmunityBio & NantKwest Non-Replicating Viral Vector NantKwest, Inc. (biotechnology company)
Ad5 S (GREVAX™ platform) Greffex (biotechnology Pre-clinical Non-Replicating Viral Vector company)
Oral Ad5 S Stabilitech Biopharma Ltd Pre-clinical Non-replicating viral vector (biotechnology company)
Researched by: Nathan Gardner 15 Last update date: August 1, 2020
Vaccine Developer(s) Current development stage Funders Related agreements/partnerships/collaborations candidate/technology Adenovirus-based + HLA- Valo Therapeutics Ltd Pre-clinical matched peptides (biotechnology company) Non-replicating viral vector
MVA expressing structural Centro Nacional Pre-clinical Jesús Serra Foundation proteins Biotecnología (CNB-CSIC) (Catalana Occidente Non-replicating viral vector (government) Group) (non-profit / funder)
Dendritic cell-based vaccine University of Manitoba Pre-clinical Canadian Government Non-replicating viral vector (academic institution) (funder)
Parainfluenza virus 5 (PIV5)- University of Georgia Pre-clinical National Institutes of Academic partnership between University of Georgia based vaccine expressing the (academic institution) Health (government / & University of Iowa spike protein funder) University of Iowa Non-replicating viral vector University licensing from the University of Georgia (academic institution) Cystic Fibrosis
Foundation (non-profit / funder) Roy J. Carver Charitable Trust (non-profit / funder) Biao He (funder) Fred C. Davison endowment (non-profit / funder)
Recombinant deactivated Bharat Biotech Pre-clinical Licensing & development agreement between Bharat rabies virus containing S1 (biotechnology company) Biotech & Thomas Jefferson University Non-replicating viral vector Thomas Jefferson University (academic institution)
Protein Subunit Adeleke University Pre-clinical Helix Biogen Consult Partnership between Adeleke University, Helix Biogen (academic institution) (general industry) Consult & Trinity Immonoefficient Laboratory
Researched by: Nathan Gardner 16 Last update date: August 1, 2020
Vaccine Developer(s) Current development stage Funders Related agreements/partnerships/collaborations candidate/technology Helix Biogen Consult Trinity Immondefficient (general industry) Laboratory (pharmaceutical Trinity Immonoefficient manufacturer) Laboratory (pharmaceutical manufacturer)
Influenza A H1N1 vector National Research Centre, Pre-clinical Egypt (research institute)
Inactivated Flu-based SARS- National Center for Genetic Pre-clinical Government CoV2 vaccine + Adjuvant Engineering and Pharmaceutical Non-replicating viral vector Biotechnology (BIOTEC), Organization (GPO), Thailand (research institute) Thailand (government) Government Pharmaceutical Organization (GPO), Thailand (government)
Protein Subunit University of San Martin Pre-clinical (academic institution) CONICET (government)
RBD protein fused with Fc of Chulalongkorn University Pre-clinical Government IgG + Adj. (academic institution) Pharmaceutical Protein Subunit Organization (GPO), Government Thailand (government) Pharmaceutical Organization (GPO), Thailand (government)
Capsid-like Particle AdaptVac (PREVENT-nCoV Pre-clinical Horizon 2020 (European Manufacturing agreement between AGC Biologics & Protein Subunit consortium) (product Union) (funder) AdaptVac development partnership) Licensing agreement between Bavarian Nordic & AdaptVac
Researched by: Nathan Gardner 17 Last update date: August 1, 2020
Vaccine Developer(s) Current development stage Funders Related agreements/partnerships/collaborations candidate/technology Grant agreement between Horizon 2020/IMI & AdaptVac Drosophila S2 insect cell ExpreS2ion (biotechnology Pre-clinical Horizon 2020 (European expression system VLPs company) Union) (funder) Protein Subunit DPX-COVID-19, Peptide IMV Inc (biotechnology Pre-clinical Collaboration for the Phase I trial between IMV & the antigens formulated in LNP company) lead study investigators Protein Subunit S protein WRAIR (government) Pre-clinical Protein Subunit USAMRIID (government)
S protein +Adjuvant National Institute of Pre-clinical Protein Subunit Infectious Disease (NIID), Japan (government) Shionogi (multinational pharmaceutical company) UMN Pharma (biotechnology company/ vaccine manufacturer / pharmaceutical manufacturer)
Peptide Vaxil Bio (biotechnology Pre-clinical Protein Subunit company)
Adjuvanted protein subunit Biological E Ltd Pre-clinical (RBD) (biotechnology company/ vaccine manufacturer / pharmaceutical manufacturer)
Peptide Flow Pharma Inc Pre-clinical Manufacturing agreement between Oakwood Labs & Protein Subunit (biotechnology company) Flow Pharma
Researched by: Nathan Gardner 18 Last update date: August 1, 2020
Vaccine Developer(s) Current development stage Funders Related agreements/partnerships/collaborations candidate/technology S protein AJ Vaccines (biotechnology Pre-clinical company / vaccine manufacturer)
VLP-recombinant protein + Osaka University (academic Pre-clinical Partnership between Osaka University, BIKEN, & Adjuvant institution) National Institutes of Biomedical Innovation, Japan BIKEN (biotechnology company) National Institutes of Biomedical Innovation, Japan (government)
S protein EpiVax (biotechnology Pre-clinical Partnership between EpiVax & University of Georgia Protein Subunit company) University of Georgia (academic institution)
Protein Subunit EPV-CoV-19 EpiVax (biotechnology Pre-clinical Crowdsourcing Licensing from EpiVax to the GAIA Vaccine Protein Subunit company) Foundation
S protein (baculovirus Sanofi Pasteur Pre-clinical BARDA (government) Development/supply agreement between Sanofi, production) (multinational GSK, & U.S. Government for 100 million doses Protein Subunit pharmaceutical company) Development & material transfer agreement GSK (multinational between Sanofi Pasteur & GSK pharmaceutical company)
Funding partnership between BARDA & Sanofi Pasteur gp-96 backbone Heat Biologics Pre-clinical Partnership between Heat Biologics & University of Protein Subunit (biotechnology company) Miami
University of Miami Manufacturing agreement for Phase I clinical trials (academic institution) between Waisman & Heat Biologics
Peptide vaccine State Research Center of Pre-clinical Protein Subunit Virology and Biotechnology Researched by: Nathan Gardner 19 Last update date: August 1, 2020
Vaccine Developer(s) Current development stage Funders Related agreements/partnerships/collaborations candidate/technology VECTOR of the Federal Service for Surveillance in Consumer Rights Protection and Human Well-being (FSRI SRC VB VECTOR), Russia (government)
Subunit vaccine State Research Center of Pre-clinical Protein Subunit Virology and Biotechnology VECTOR of the Federal Service for Surveillance in Consumer Rights Protection and Human Well-being (FSRI SRC VB VECTOR), Russia (government)
S1 or RBD protein Baylor College of Medicine Pre-clinical Tito’s Handmade Vodka Partnership between the Baylor College of Medicine, Protein Subunit (academic institution) (general) Texas Children’s Hospital & PATH Texas Children’s Hospital (non-profit) Baylor College of Medicine (academic institution)
Subunit protein, plant iBio (biotechnology Pre-clinical Development partnership between iBio & CC- produced company) Pharming) CC-Pharming (biotechnology company)
Recombinant protein, Saint-Petersburg Scientific Pre-clinical nanoparticles (based on S- Research Institute of protein and other epitopes) Vaccines and Serums Protein Subunit (government)
Researched by: Nathan Gardner 20 Last update date: August 1, 2020
Vaccine Developer(s) Current development stage Funders Related agreements/partnerships/collaborations candidate/technology COVID-19 XWG-03 Innovax Biotech Pre-clinical Development agreement between GSK & Innovax truncated S (spike) proteins (biotechnology company / Protein Subunit vaccine manufacturer) Partnership between Innovax & Xiamen University Xiamen University (academic institution) GSK (multinational pharmaceutical company)
Adjuvanted microsphere VIDO-InterVac (University of Pre-clinical Canada Foundation for peptide Saskatchewan) (academic Innovation Protein Subunit institution) (government) Western Economic Diversification - Regional Economic Growth Through Innovation Program (funder)
Synthetic Long Peptide OncoGen (pharmaceutical Pre-clinical Vaccine candidate for S and manufacturer) M proteins Oral E. coli-based protein MIGAL Galilee Research Pre-clinical OurCrowd (funder) expression system of S and N Institute (research institute) proteins Protein Subunit Nanoparticle vaccine LakePharma, Inc. (vaccine Pre-clinical Protein Subunit manufacturer)
Plant-based subunit Baiya Phytopharm Pre-clinical (RBD-Fc + Adjuvant) (biotechnology company) Protein Subunit Chula Vaccine Research Center (academic institution)
Researched by: Nathan Gardner 21 Last update date: August 1, 2020
Vaccine Developer(s) Current development stage Funders Related agreements/partnerships/collaborations candidate/technology OMV-based vaccine Quadram Institute Pre-clinical Protein Subunit Biosciences (academic institution)
OMV-based vaccine BiOMViS Srl (biotechnology Pre-clinical Partnership between BiOMViS Srl & University of Protein Subunit company) Trento
University of Trento (academic institution)
Structurally modified Lomonosov Moscow State Pre-clinical spherical particles of the University (academic tobacco mosaic virus (TMV) institution) Protein Subunit Spike-based University of Alberta Pre-clinical Alberta Innovates Partnership between Tonix Pharma & University of Protein Subunit (academic institution) (funder) Alberta Canadian Institutes of Health Research (government)
Recombinant S1-Fc fusion AnyGo Technology (general Pre-clinical protein industry) Protein Subunit Recombinant protein Yisheng Biopharma Pre-clinical Protein Subunit (multinational pharmaceutical company)
Recombinant S protein in IC- Vabiotech (Vietnam Pre-clinical Partnership between University of Bristol & BEVS Ministry of Health) Vabiotech Protein Subunit (government)
Orally delivered, heat stable Applied Biotechnology Pre-clinical subunit Institute, Inc. (biotechnology company)
Peptides derived from Spike Axon Neuroscience SE Pre-clinical protein (biotechnology company)
Researched by: Nathan Gardner 22 Last update date: August 1, 2020
Vaccine Developer(s) Current development stage Funders Related agreements/partnerships/collaborations candidate/technology Protein Subunit Protein Subunit MOGAM Institute for Pre-clinical Biomedical Research (non- profit) GC Pharma (biotechnology company)
RBD-based vaccine Neovii (multinational Pre-clinical Licensing agreement between Neovii & Tel Aviv Protein Subunit pharmaceutical company) University Tel Aviv University (academic institution)
Outer Membrane Vesicle Intravacc (contract research Pre-clinical Development agreement between Intravacc & (OMV)-peptide organization) Epivax) Protein Subunit Epivax (biotechnology company)
Spike-based (epitope ImmunoPrecise (contract Pre-clinical screening) research organization) LiteVax BV (biotechnology company)
YF17D Vector KU Leuven (academic Pre-clinical Replicating Viral Vector institution)
Measles Vector Cadila Healthcare Limited Pre-clinical Replicating Viral Vector (multinational pharmaceutical company)
Measles Vector Merck (multinational Pre-clinical CEPI (funder) Development partnership between Institute Pasteur, Replicating Viral Vector pharmaceutical company) Themis & University of Pittsburg
Institute Pasteur (non- Funding partnership between CEPI & Institute profit) Pasteur
Researched by: Nathan Gardner 23 Last update date: August 1, 2020
Vaccine Developer(s) Current development stage Funders Related agreements/partnerships/collaborations candidate/technology Themis (biotechnology company) University of Pittsburg Center for Vaccine Research (academic institution)
Measles Vector State Research Center of Pre-clinical Replicating Viral Vector Virology and Biotechnology VECTOR of the Federal Service for Surveillance in Consumer Rights Protection and Human Well-being (FSRI SRC VB VECTOR), Russia (government)
Measles Virus (S, N targets) DZIF – German Center for Pre-clinical Live attenuated virus Infection Research (government) CanVirex AG (biotechnology company)
Horsepox vector expressing S Tonix Pharma Pre-clinical Development agreement between Tonix & Southern protein (biotechnology company) Research Replicating Viral Vector Southern Research (contract research organization)
Live viral vectored vaccine BiOCAD (biotechnology Pre-clinical based on attenuated company / vaccine influenza virus backbone manufacturer) (intranasal) IEM (government) Replicating Viral Vector Recombinant vaccine based State Research Center of Pre-clinical on Influenza A virus Virology and Biotechnology (intranasal) VECTOR of the Federal Replicating Viral Vector Service for Surveillance in Consumer Rights Protection Researched by: Nathan Gardner 24 Last update date: August 1, 2020
Vaccine Developer(s) Current development stage Funders Related agreements/partnerships/collaborations candidate/technology and Human Well-being (FSRI SRC VB VECTOR), Russia (government)
Attenuated Influenza Fundação Oswaldo Cruz Pre-clinical expressing an antigenic (non-profit) portion of the Spike protein Instituto Butantan Replicating Viral Vector (academic institution)
Influenza vector expressing University of Hong Kong Pre-clinical CEPI (funder) Funding partnership between CEPI & University of RBD (academic institution) Hong Kong Replicating Viral Vector Replication-competent VSV IAVI (non-profit) Pre-clinical BARDA (funder) Manufacturing agreement between IAVI & Batavia chimeric virus technology Merck (multinational (VSVΔG) delivering the SARS- Development agreement between IAVI & Merck pharmaceutical company) CoV-2 Spike (S) glycoprotein Replicating Viral Vector Funding partnership between BARDA, IAVI & Merck VSV-S University of Western Pre-clinical Canada (government) Replicating Viral Vector Ontario (academic institution)
VSV vector State Research Center of Pre-clinical Replicating Viral Vector Virology and Biotechnology VECTOR of the Federal Service for Surveillance in Consumer Rights Protection and Human Well-being (FSRI SRC VB VECTOR), Russia (government)
VSV vector Israel Institute for Biological Pre-clinical Replicating Viral Vector Research (research institute)
Researched by: Nathan Gardner 25 Last update date: August 1, 2020
Vaccine Developer(s) Current development stage Funders Related agreements/partnerships/collaborations candidate/technology Weizmann Institute of Science (academic institution)
M2-deficient single University of Wisconsin– Pre-clinical Development agreement (including licensing) replication (M2SR) influenza Madison (academic between University of Wisconsin–Madison, FluGen & vector institution) Bharat Biotech Replicating Viral Vector FluGen (biotechnology
company) Bharat Biotech (biotechnology company)
Newcastle disease virus Intravacc (contract research Pre-clinical Development partnership between Utrecht vector (NDV-SARS-CoV- organization) University, Wageningen Bioveterinary Research & 2/Spike) Intravacc Wageningen Bioveterinary Replicating Viral Vector Research (contract research organization) Utrecht University (academic institution)
Avian paramyxovirus vector Lancaster University Pre-clinical (APMV) (academic institution) Replicating Viral Vector LNP-mRNA Translate Bio (biotechnology Pre-clinical Development agreement (including pre-existing company) licensing agreement) between Translate & Sanofi) Sanofi Pasteur (multinational pharmaceutical company)
LNP-mRNA CanSino Biologics Pre-clinical Development agreement (including IP rights) (biotechnology company / between CanSino Biologics & Precision NanoSystems vaccine manufacturer) Precision NanoSystems (biotechnology company)
Researched by: Nathan Gardner 26 Last update date: August 1, 2020
Vaccine Developer(s) Current development stage Funders Related agreements/partnerships/collaborations candidate/technology LNP-encapsulated mRNA Fudan University (academic Pre-clinical Development collaboration between Fudan cocktail encoding VLP institution) University, Shanghai JiaoTong University & RNACure RNA Biopharma Shanghai Jiao Tong
University (academic institution) RNACure Biopharma (biotechnology company)
LNP-encapsulated mRNA Fudan University (academic Pre-clinical Development collaboration between Fudan encoding RBD institution) University, Shanghai JiaoTong University, and RNA RNACure Biopharma Shanghai Jiao Tong University (academic institution) RNACure Biopharma (biotechnology company / vaccine manufacturer)
Replicating Defective SARS- Centro Nacional Pre-clinical Jesús Serra Foundation CoV-2 derived RNAs Biotecnología (CNB-CSIC) (Catalana Occidente (government) Group) (funder)
LNP-encapsulated mRNA University of Tokyo Pre-clinical Development partnership between University of (academic institution) Tokyo & Daiichi-Sankyo
Daiichi-Sankyo (multinational pharmaceutical company)
Liposome-encapsulated BIOCAD (biotechnology Pre-clinical mRNA company / vaccine manufacturer)
Several mRNA candidates RNAimmune, Inc. Pre-clinical (biotechnology company)
Researched by: Nathan Gardner 27 Last update date: August 1, 2020
Vaccine Developer(s) Current development stage Funders Related agreements/partnerships/collaborations candidate/technology mRNA State Research Center of Pre-clinical Virology and Biotechnology VECTOR of the Federal Service for Surveillance in Consumer Rights Protection and Human Well-being (FSRI SRC VB VECTOR), Russia (government) mRNA China CDC (government) Pre-clinical Development partnership between China CDC, Tongji University & Stermina Therapeutics Tongji University (academic institution) Stermina Therapeutics (biotechnology company)
LNP-mRNA Chula Vaccine Research Pre-clinical Center (academic institution) University of Pennsylvania (academic institution) mRNA - intranasal delivery eTheRNA, EpiVax, Nexelis, Pre-clinical system REPROCELL, and the Centre for the Evaluation of Vaccination of the University of Antwerp (Product development partnership)
mRNA Greenlight Biosciences Pre-clinical Flu Lab (funder) (biotechnology company) Xeraya Capital (funder)
Researched by: Nathan Gardner 28 Last update date: August 1, 2020
Vaccine Developer(s) Current development stage Funders Related agreements/partnerships/collaborations candidate/technology Baird Capital (funder) mRNA IDIBAPS-Hospital Clinic Pre-clinical (non-profit)
S protein integrated in HIV IrsiCaixa AIDS Research Pre-clinical Grifols (multinational Development partnership between the IrsiCaixa AIDS VLPs IRTA-CReSA (research pharmaceutical Research Institute, the Barcelona Supercomputing institute) company) Center (BSC) and the Animal Health Research Center IRTA-CReSA The Animal Health Research Center IRTA-CReSA (research institute) Barcelona Supercomputing Centre (non-profit) Grifols (multinational pharmaceutical company)
VLP + Adjuvant Mahidol University Pre-clinical GPO (government) (academic institution) Government Pharmaceutical Organization (GPO), Thailand (government) Siriraj Hospital (non-profit)
VLP, lentivirus and Navarrabiomed, Pre-clinical baculovirus vehicles Oncoimmunology Group (government)
VLP based on RBD displayed Saiba GmbH (biotechnology Pre-clinical Partnership between Bern University & Saiba GmbH on virus-like particles company)
ADDomerTM multiepitope Imophoron Ltd Pre-clinical display (biotechnology company) VLP
Researched by: Nathan Gardner 29 Last update date: August 1, 2020
Vaccine Developer(s) Current development stage Funders Related agreements/partnerships/collaborations candidate/technology Max Planck Centre (Bristol University) (academic institution)
VLP Doherty Institute Pre-clinical Jack Ma Foundation (partnership between the (funder) University of Melbourne & Victoria government The Royal Melbourne (government) Hospital) (product development partnership) a2 Milk Company (general industry)
VLP OSIVAX (biotechnology Pre-clinical EIC Accelerator (funder) company) eVLP ARTES Biotechnology Pre-clinical (biotechnology company)
VLPs peptides/whole virus University of Sao Paulo Pre-clinical (academic institution)
Unknown Tulane University (academic Pre-clinical Brown Foundation institution) (funder)
Unknown Université Laval (academic Pre-clinical Canadian Government institution) (government)
Unknown Adeleke University Pre-clinical Trinity Immunodeficient (academic institution) Laboratory (pharmaceutical manufacturer) Helix Biogen Consult (general industry)
Inactivated + alum KM Biologics (biotechnology Pre-clinical company)
Researched by: Nathan Gardner 30 Last update date: August 1, 2020
Vaccine Developer(s) Current development stage Funders Related agreements/partnerships/collaborations candidate/technology Inactivated Selcuk University (academic Pre-clinical institution)
DNA Ege University (academic Pre-clinical institution)
DNA plasmid vaccine RBD&N Scancell (biotechnology Pre-clinical Development partnership between Scancell & company) University of Nottingham University of Nottingham (academic institution) Nottingham Trent University (academic institution)
Codon deoptimized live Mehmet Ali Aydinlar Pre-clinical attenuated vaccines University (academic institution)
Acıbadem Labmed Health Services A.S. (contract research organization)
Sendai virus vector, Non- ID Pharma (biotechnology Pre-clinical Replicating Viral Vector company)
National Institute of Infectious Diseases, Japan (government)
Adenovirus-based vaccine, Ankara University (academic Pre-clinical Non-Replicating Viral Vector institution)
Recombinant S protein, Izmir Biomedicine and Pre-clinical Protein Genome Center (academic institution) Peptide + novel adjuvant, Bogazici University Pre-clinical Protein Subunit (academic institution)
Researched by: Nathan Gardner 31 Last update date: August 1, 2020
Vaccine Developer(s) Current development stage Funders Related agreements/partnerships/collaborations candidate/technology S subunit intranasal liposomal University of Virginia Pre-clinical formulation with GLA/3M052 (academic institution) adjs., Protein Subunit mRNA Selcuk University (academic Pre-clinical institution) VLP Middle East Technical Pre-clinical University (academic institution)
RBD-protein, Protein Subunit Mynvax (biotechnology Pre-clinical company)
VSV-S, Replicating Viral Aurobindo (pharmaceutical Pre-clinical Vector manufacturer)
HGCO19 Gennova (biotechnology Pre-clinical Development agreement between Gennova & HDT Self-amplifying RNA company) Bio HDT Bio (biotechnology company)
Inactivated Erciyes University (academic Pre-clinical institution)
Adeno5-based, Non- Erciyes University (academic Pre-clinical replicating viral vector institution)
VLP Bezmialem Vakif University Pre-clinical (academic institution)
HDT-301, RNA University of Washington Pre-clinical (academic institution)
National Institutes of Health Rocky Mountain Laboratories (government)
Researched by: Nathan Gardner 32 Last update date: August 1, 2020
Vaccine Developer(s) Current development stage Funders Related agreements/partnerships/collaborations candidate/technology HDT Bio Corp (biotechnology company)
Protein subunit plant virus University of California, San Early development National Science nanotechnology formulated Diego (academic institution) Foundation (funder) as injectable and microneedle patch Protein subunit S protein University of Cambridge Early development (academic institution) DIOSynVax – spinout of U. of Cambridge (academic institution) RNA Vaccine GeneOne Life Science Early development Pre-Existing exclusive license agreement between (biotechnology company) GeneOne & Houston Methodist Houston Methodist Hospital (non-profit) RNA ZIP-1642 Ziphius Therapeutics Early development Development partnership between Ziphius & Ghent Combination of mRNA (biotechnology company) University molecules, encoding multiple Ghent University (academic SARS-CoV-2 antigens institution) Enveloped virus-like particle VBI Vaccines (biotechnology Early development Development partnership between VBI & NRCC (eVLP) company / vaccine Pan-coronavirus vaccine manufacturer) candidate, targeting COVID- National Research Council 19, SARS and MERS spike of Canada (government) protein Unknown Catholic University, Early development Millennium Institute of Immunology and Immunotherapy (academic institution)
Researched by: Nathan Gardner 33 Last update date: August 1, 2020
Vaccine Developer(s) Current development stage Funders Related agreements/partnerships/collaborations candidate/technology Technological Consortium in Clinical Molecular Biomedicine (non-profit) Vaccine: ISR-50 ISR Immune System Early development Regulation (biotechnology company) Unknown Covaxx (biotechnology Early development company) HaloVax™: Self-assembling Voltron Therapeutics Early development Analog Devices Joint Venture (HaloVax™, LLC) between Voltron and vaccine (biotechnology company) Foundation (funder) Hoth for the development of HaloVax™ Fusion protein of a heat The Vaccine & shock protein and Avidin with Research agreement between Voltron and Immunotherapy Center at biotinylated immunogenic Massachusetts General Massachusetts General peptides Hospital (research institute) Licensing agreement for Massachusetts General’s Hoth Therapeutics, Inc. Self-Assembling Vaccine platform between (biotechnology company) Massachusetts General and Voltron
Gene-encoded antibody SmartPharm Therapeutics Early development Research & development agreement between vaccine non-viral (biotechnology company) SmartPharm & Sorrento Therapeutics nanoparticle delivery Sorrento Therapeutics (biotechnology company)
Unknown Vir Biotechnology Early development Equity investment & development agreement (biotechnology company) between Vir & GSK GSK (multinational pharmaceutical company)
Unknown Emergex Vaccines (vaccine Early development Academic-Industry Development Partnership manufacturer) between Emergex Vaccines & George Mason University George Mason University - National Center for Biodefense and Infectious
Researched by: Nathan Gardner 34 Last update date: August 1, 2020
Vaccine Developer(s) Current development stage Funders Related agreements/partnerships/collaborations candidate/technology Diseases (NCBID) (academic institution) AVI-205 AbVision (biotechnology Pre-clinical company) Unknown SK Biosciences Pre-clinical Gates Foundation Funding partnership between Gates Foundation & SK (multinational (funder) Biosciences pharmaceutical company) MV-014-210, live attenuated Meissa Vaccines Pre-clinical vaccine (biotechnology company) Unknown Precision Vaccines Program Early development - Boston Children's Hospital (research institute) TerraCoV2 Oragenics (Noachis Terra) Early development Worldwide, non-exclusive license agreement (biotechnology company) between NIAID and Noachis Terra
Aragen Bioscience (contract Development agreement between Aragen & research organization) Oragenics Recombinant LVS ΔcapB University of California, Los Early development Vectored vaccine expressing Angeles (academic multiple SARS-CoV-2 antigens institution)
Researched by: Nathan Gardner 35 Last update date: August 1, 2020